Breaking Preview: Ribo to Unveil Global First Phase IIa Clinical Data of Lead Asset Vortosiran at CPIC, Followed by Dedicated Data Briefing with Live Streaming

July 8, 2026·Suzhou China & Mölndal Sweden

Suzhou Ribo Life Science Co., Ltd. (Ribo, 06938.HK) pre-announces a major clinical update: it will publicly disclose for the first time the Phase IIa clinical study data of vortosiran (RBD4059), its flagship siRNA therapeutic candidate for coronary artery disease (CAD), at the inaugural China Pharmaceutical Innovation Conference (CPIC), taking place in Shanghai from July 22 to 24.

Ribo is scheduled to deliver a plenary keynote presentation on July 22 to formally release the full findings from this Phase IIa clinical program. Immediately after the keynote address, Ribo will host an exclusive dedicated briefing session focused on vortosiran’s Phase IIa dataset, which will be broadcast live online for remote audiences.

Members of Ribo’s senior management team will be joined by Professor Carolyn S.P. Lam, a world-leading cardiologist and Principal Investigator for vortosiran’s clinical trial. Together they will conduct a comprehensive analysis of trial outcomes, while engaging in open Q&A and direct dialogue with attendees.

Detailed registration and live stream access information are available in the below invitation letter.

About vortosiran (RBD4059) 

Vortosiran (RBD4059) is the world's first siRNA drug targeting coagulation factor XI (FXI), independently developed by Ribo based on its RiboGalSTAR^TM liver-targeting platform. By specifically inhibiting factor XI gene expression, it blocks the activation of the intrinsic coagulation pathway, achieving precise anticoagulant and antithrombotic effects. Furthermore, vortosiran maintains sustained FXI inhibition for up to six months, and provides a groundbreaking solution to address the clinical challenge of poor compliance with long-term anticoagulation therapy. Currently, vortosiran has completed its Phase IIa clinical trial in Europe and has submitted Phase IIb clinical trial applications (CTA) to European Medicines Agency (EMA) for stroke prevention in atrial fibrillation (SPAF) and venous thromboembolism (VTE) in April and May 2026, respectively.